Post-traumatic stress is one of the most marketed off-label uses of HBOT, especially to veterans. Clinic ads promise relief where standard care has plateaued. The trial record is mixed and lags far behind the marketing.
This page lays out what the stress disorder trials actually show. The short version up front: small open-label studies show gains, sham-controlled trials in service members have largely been negative, and the VA still researches but does not pay for the protocol.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | NOT approved for stress disorder |
| UHMS classification | Not on the 14 approved indications list |
| Medicare coverage | NOT covered for stress disorder |
| TRICARE / VA coverage | Generally not covered; VA still researching |
| Typical out-of-pocket | $6,000-$15,000 for a 40-session course |
| Evidence grade | Low — sham-controlled RCTs largely negative |
The evidence
Stress disorder HBOT data is tied tightly to the brain injury trial set. The two often run together in veteran cohorts. The signal is uneven.
The Cifu and colleagues 2014 Annals of Neurology trial, PMID 24255008 randomized 61 Marines with combat-related concussion symptoms and high stress disorder rates to sham, 1.5 ATA, or 2.0 ATA. By three months, no arm beat sham on any stress disorder measure.
The Wolf and colleagues 2012 Journal of Neurotrauma trial, PMID 22455496 was the earlier sham-controlled study. The HBOT and sham arms both improved. No edge for the active treatment was seen on stress disorder symptoms either.
The Harch and colleagues 2017 Medical Gas Research case-control paper, PMID 29152209 ran 30 military subjects with brain injury and stress disorder symptoms. The paper reported drops in symptom severity, and about 52% no longer met stress disorder criteria. No sham group was used.
The Harch and colleagues 2020 Medical Gas Research trial, PMID 32189664 ran 56 civilians and veterans against wait-list controls. Stress disorder scores fell in the HBOT arm. The control arm was wait-list, not sham, which weakens the comparison.
The Doenyas-Barak and colleagues 2022 PLoS ONE trial, PMC 8863239 studied 35 veterans with treatment-resistant stress disorder in a randomized, sham-controlled design. The HBOT arm showed gains on stress disorder severity and brain imaging. The trial was single-center in Israel and used a delayed-treatment design.
The Doenyas-Barak follow-up 2022, PMID 36433746 reported long-term data from the same group. Gains persisted at one year.
A 2024 PMC narrative review on HBOT for stress disorder in veterans, PMC 10630921 summed up the broader picture. The review noted small samples, mixed findings, and a heavy reliance on one research group.
A 2024 systematic review and dosage analysis on HBOT efficacy in stress disorder, PMC 11179433 pooled the trial data. The review found no firm consensus and called for larger sham-controlled trials.
The pattern is striking. Open-label and wait-list trials show gains. The two large US sham-controlled trials in service members were negative.
The one Israeli sham-controlled study was positive. Independent replication outside that group is missing.
Why people pursue this anyway
Stress disorder care is hard. Standard exposure therapy and SSRIs leave many veterans short of full recovery, and the suicide rate in this group is tragic. The promise of more relief pulls in desperate searchers.
Wellness chains, veteran-focused clinics, and a long tail of small operators market HBOT for stress disorder. Independent operators run chambers from Sechrist Industries, Perry Baromedical, OxyHealth, Summit to Sea, ETC Biomedical, and Healing Chambers International. Veterans groups have pushed Congress to cover the protocol.
The honest gap is that veteran testimonials and one positive Israeli trial do not equal what controlled US trials have shown. Veterans deserve to know that gap.
For deeper context on the marketing-vs-evidence split, see our evidence-vs-marketing review of clinic chains, our analysis of institutional silence on HBOT, and our companion brain injury evidence atlas.
What clinical guidelines say
The US Department of Defense and Department of Veterans Affairs clinical practice guideline for stress disorder does not list HBOT. The VA has funded several trials and continues to research the question.
The American Psychiatric Association stress disorder guidelines list trauma-focused therapy and SSRIs as the recommended path. HBOT is not on the list. The Society of Biological Psychiatry has not endorsed HBOT.
UHMS does not include stress disorder on its 14 approved indications list. The official UHMS HBO indications page, 2024 is the source of truth.
The silence from these bodies is not an oversight. It reflects the trial record. Two large negative US sham-controlled trials carry more weight than open-label gains.
Cost versus evidence
A 40-session course at a wellness clinic runs $6,000 to $15,000. Premium chain packages can run higher.
Veterans face this cost without TRICARE or VA support outside of research protocols. HSA and FSA accounts may or may not accept the claim.
That price stacks against negative US sham trials and one positive Israeli trial. The math asks a hard question — is this the best use of veteran care dollars versus proven trauma-focused therapy?
The framing is not that no veteran should try this. The framing is that the trial record does not match the marketing.
What to ask your physician
Patients weighing HBOT for stress disorder can ask several questions.
What is the FDA status — the answer is "not approved." Have I had a trial of proven trauma-focused therapy and SSRIs — the answer should be yes first. What does my VA mental-health team think — the answer is usually cautious.
For chamber-type details, see our hard-shell vs soft-shell chamber explainer. The Harch and Israeli protocols use hard chambers from makers such as Sechrist Industries and Perry Baromedical, not the soft chambers from OxyHealth and Summit to Sea found at wellness studios.
Distinguishing from FDA-approved uses
Stress disorder sits very differently from approved HBOT uses. The approved list of 14 conditions — carbon monoxide poisoning, dive injury, bone infection, diabetic foot wounds, and ten others — all have decades of backing data.
Our carbon monoxide poisoning evidence atlas and decompression sickness evidence atlas show what real FDA-approved HBOT evidence looks like — many trials, multi-center designs, and a settled mechanism.
Stress disorder does not have that backing. The honest call is to label it "investigational" and let veterans decide with open eyes.
Frequently asked questions
Is HBOT FDA-approved for stress disorder?
No. The FDA recognizes 14 conditions for HBOT and stress disorder is not among them. The UHMS approved indications list, current 2024, also does not include stress disorder.
What did the major US sham-controlled trials show?
Wolf 2012 and Cifu 2014 both compared HBOT to sham in service members with brain injury and high stress disorder rates. Neither found a benefit for the active treatment on stress disorder symptoms at three months. The Cifu paper is the most rigorous design in the literature and was firmly negative.
Will TRICARE, the VA, or Medicare cover this?
Generally no. Medicare and most commercial plans cover HBOT only for the 14 approved indications. The VA has funded research but does not cover routine off-label HBOT. Most veterans pay out of pocket.
Why is the Israeli trial different?
The 2022 Doenyas-Barak trial was sham-controlled but used a delayed-treatment design and ran at one center. The signal was positive. Independent replication outside that group is missing, which is the same pattern seen across HBOT off-label work.
What proven care should come first?
Trauma-focused therapy such as prolonged exposure, cognitive processing therapy, and EMDR plus SSRI medication. The VA and APA guidelines recommend these first-line.
Sources
- Cifu and colleagues 2014, PMID 24255008
- Wolf and colleagues 2012, PMID 22455496
- Harch case-control 2017, PMID 29152209
- Harch and colleagues 2020, PMID 32189664
- Doenyas-Barak randomized trial 2022, PMC 8863239
- Doenyas-Barak follow-up 2022, PMID 36433746
- Veteran narrative review 2024, PMC 10630921
- Systematic review of HBOT in PTSD 2024, PMC 11179433
- UHMS HBO Indications List, 2024
Medical disclaimer
This page is medical journalism and not medical advice. HBOT for post-traumatic stress disorder is an investigational off-label use without FDA approval. Standard care including trauma-focused therapy, SSRI medication, and clinical follow-up under a mental-health team remains the guideline-recommended path. Talk to your VA mental-health team or psychiatrist before pursuing any out-of-pocket HBOT protocol. If you are in crisis, the Veterans Crisis Line is 988 then press 1. This page does not diagnose or substitute for professional medical care.